Paul Dolan
Publications and Insights
- Publication: Taking STRIDES: The Value of Diagnostics Against AMR
- Publication: Understanding the Full Value of Long-Acting Therapies: less is more?
- Publication: Analysing Global Immunisation Expenditure
- Publication: The BRAVER Roadmap to Broader Assessment of the Value of Health Interventions in the Asia-Pacific Region
- Publication: Employer Costs from Respiratory Infections
- Insight: R&D For New Drugs To Tackle AMR Is A High Return Investment For All EU Member States
- Bulletin: Overcoming combination therapy challenges
- Publication: Unlocking the Value of Combination Therapies
- Insight: Using Target Product Profiles (TPPs) to improve diagnostic testing for cancer
- Publication: Socio-Economic Value of Adult Immunisation Programmes
- Publication: Developing a Conceptual Framework of Healthcare System Pressure
- Insight: Breaking the European Deadlock: Part 3 – Revenue Guarantee and Subscription Models for New Antibiotics
- Insight: Breaking the European Deadlock: Part 2 – Transferable Exclusivity Vouchers – Effective Pull Incentive or a Policy Distraction?
- Publication: Capturing the Broader Value of Antibiotics
- Insight: OHE’s AMR consultation response
- Bulletin: The power of better diagnostics
- Insight: New Drugs to Tackle Antimicrobial Resistance: Breaking the European Deadlock: Part 1 – Defining Objectives
- Insight: Around The World in HTAs: The Netherlands – 5 Routes for New Tech
- Publication: A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance
- Publication: Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechanism
- Insight: Cost-effectiveness Analysis of Gene Therapies for Inherited Eye Disease: Are Current Discounting Approaches Too Short-sighted?
- Publication: The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe
- Insight: Combination Therapies: A Step Forward to the Value Attribution Problem
- Publication: Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies
- Insight: The Economics of Antibiotics – Part 4: What Does the Antibiotics Market of the Future Look Like?
- Insight: The Economics of Antibiotics – Part 3: Creating a Healthy Global Market for New Antibiotics
- Insight: The Economics of Antibiotics – Part 2: Value Assessment within the NICE-NHS AMR Pilot
- Insight: The Economics of Antibiotics – Part 1: Why NICE and NHS England are Testing an Innovative HTA and Payment Model to Tackle Antimicrobial Resistance
- Publication: Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies
- Insight: International Women’s Day: Why We #Choosetochallenge
- Publication: Making Outcome-Based Payment a Reality in the NHS. Phase Two: Practical Considerations
- Publication: After the Transplant: Potential Benefits for the NHS and UK Kidney Transplant Patients
- Publication: The Value of Vaccines in Maintaining Health System Capacity in England
- Publication: Working Towards a Sustainable, Healthy Market for Vaccines: a Comprehensive Framework to Support Policy Dialogue and Decision-Making
- Publication: Realising The Broader Value of Vaccines in the UK: Ready for Prime Time?
- Publication: Why we need a new Outcomes-based Value Attribution Framework for Combination Regimens in Oncology
- Publication: The BRAVE Initiative: The BRAVE Narrative for Broad Recognition of Value in Vaccines Engagement
- Publication: Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies
- Publication: The Broader Value of Vaccines: The Return on Investment From a Governmental Perspective
- Publication: Using Happiness to Value Health